LM11A-31 clinical trials
Also written LM11A-31.
How each study uses LM11A-31 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the LM11A-31 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LM11A-31
- 3
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 3
Adam Boxer (2) · University of North Carolina, Chapel Hill (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses LM11A-31 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- LM11A-31 Safety and Tolerability in Aging People Living With HIV and Neurocognitive ImpairmentNot yet recruitingPhase 1/2University of North Carolina, Chapel HillNCT07934186Written as LM11A-31
- The Progressive Supranuclear Palsy Clinical Trial PlatformRecruitingPhase 2Adam BoxerNCT07173803Written as LM11A-31
- The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31Enrolling by invitationPhase 2Adam BoxerNCT07264283Written as LM11A-31
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call LM11A-31 · ClinicalTrials.gg INT006143
- MeSH (NLM) C575077LM11A-31One source ClinicalTrials.gov
- Wikidata Q82490040LM11A-31One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C575077 | LM11A-31 | One source ClinicalTrials.gov |
| Wikidata | Q82490040 | LM11A-31 | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.